This week’s research roundup features: Understanding "Patient refuses" among 90+ year old patients with cancer or presumed cancer.
Partnering with Mayo Clinic has helped St. Clair Health improve patient care and gain a new competitive advantage in pharmacogenetics.
Featured Abstract: A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy.
Guided by a patient-centric philosophy, Mayo Clinic Laboratories has a unique internal structure of quality specialists, coordinators, and engineers who constantly evaluate and improve laboratory operations. This structure supports a host of quality assurance activities.
As director of Regulatory Affairs for the Department of Laboratory Medicine and Pathology, Shannon Bennett helps safeguard Mayo Clinic’s reputation for quality care by ensuring that its clinical laboratories operate at the highest level of regulatory compliance.
Featured Abstract: Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities.
This unique Mayo Clinic resource offers a novel portal into the study of gene mutations before they cause breast cancer.
Featured abstract: Nuclear GSK-3β and oncogenic KRas lead to the retention of pancreatic ductal progenitor cells phenotypically similar to those seen in IPMN.
Working together, Mayo Clinic laboratory medicine specialists and clinicians helped Elyn Simmons get her life back — and welcome two new lives to the world.
As a clinical laboratory technologist, Daniel Kronemann enjoys going beyond his day-to-day work as he explores new ways to enhance processes and systems in Bacteriology.
Featured abstract: Substance use screening in transplant populations.
Top highlights include: Monoclonal and oligoclonal anti-Platelet Factor 4 antibodies mediate VITT.
In her role as a proposal writer, Lisa Wortman Raring helps show clients everything Mayo Clinic Laboratories has to offer, making it clear how the organization can best meet their needs and the needs of their patients.